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Abstract
Background: During the 2009 H1N1 pandemic, pregnant women were prioritized to receive the unadjuvanted or MF59H-
adjuvanted pandemic A (H1N1) 2009 monovalent vaccines (‘‘2009 H1N1 vaccines’’) in Taiwan regardless of stage of
pregnancy. Monitoring adverse events following 2009 H1N1 vaccination in pregnant women was a priority for the mass
immunization campaign beginning November 2009.
Methods/Findings: We characterized reports to the national passive surveillance from November 2009 through August
2010 involving adverse events following 2009 H1N1 vaccines among pregnant women. Reports from the passive
surveillance were matched to a large-linked database on a unique identifier, date of vaccination, and date of diagnosis in a
capture-recapture analysis to estimate the true number of spontaneous abortion after 2009 H1N1 vaccination. We verified
16 spontaneous abortions, 11 stillbirths, 4 neonatal deaths, 4 nonpregnancy-specific adverse events, and 2 inadvertent
immunizations in recipients who were unaware of pregnancy at time of vaccination. The Chapman capture-recapture
estimator of true number of spontaneous abortion after 2009 H1N1 vaccination was 329 (95% confidence interval [CI] 196–
553). Of the 14,474 pregnant women who received the 2009 H1N1 vaccines, the estimated risk of spontaneous abortion was
2.3 (95% CI, 1.4–3.8) per 100 pregnancies, compared with a local background rate of 12.8 (95% CI, 12.8–12.9) per 100
pregnancies.
Conclusions: The passive surveillance provided rapid initial assessment of adverse events after 2009 H1N1 vaccination
among pregnant women. Its findings were reassuring for the safety of 2009 H1N1 vaccines in pregnancy.
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Introduction
Pregnant women are at higher risk for complications and death
from pandemic A (H1N1) 2009 (‘‘2009 H1N1’’) infection [1–3].
This increased risk of morbidity and mortality has been observed
in two previous influenza pandemics (1918–19 and 1957–58) and
with seasonal influenza [4–6]. In Taiwan, pregnant women
infected with 2009 H1N1 were 2.7 times more likely to be
hospitalized than nonpregnant women of reproductive age, and
50% of the hospitalized required intensive care [7]. On
November 1, 2009, the Taiwan government began a nationwide
2009 H1N1 vaccination program using two types of 2009 H1N1
vaccines: an inactivated vaccine without adjuvant (Adimmune
Corporation, Taichung, Taiwan) and an MF59H-adjuvanted
vaccine (Novartis Vaccines and Diagnostics, Sovicille, Italy). The
Advisory Committee on Immunization Practices in Taiwan
recommended and prioritized pregnant women to receive either
the unadjuvanted or the MF59H-adjuvanted 2009 H1N1
vaccines, regardless of stage of pregnancy.
Because the manufacturing process for 2009 H1N1 vaccine
without adjuvant was the same as those used for seasonal influenza
vaccine, the safety profile to pregnant women and their infants was
expected to be the same as the seasonal vaccine product, which
has an excellent safety record [6]. Information about the safety of
MF59H-adjuvanted influenza vaccine in pregnancy, however, was
limited as pregnant women are classically excluded from
participation in clinical trials of new vaccines [8]. Beginning
November 2009, a postlicensure safety surveillance strategy has
been implemented in Taiwan to rapidly identify and evaluate new
or unusual adverse events among 2009 H1N1 vaccine recipients
[9]. We report on the adverse event profile following 2009 H1N1
vaccines in pregnant women.
Materials and Methods
Data collection
Taiwan Centers for Disease Control (TCDC) and Taiwan Food
and Drug Administration collaboratively established a national
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tion (AEFI) in concert with the 2009 H1N1 vaccination program
[9]. Patients or their parents, healthcare providers, manufacturers,
and others were encouraged to report any health event that occurs
in patients after receipt of 2009 H1N1 vaccines at any time
interval to the system, regardless of causality. Reports were
categorized as serious if the adverse event involved death, life-
threatening illness, hospitalization, prolongation of hospitalization,
permanent disability, or congenital anomaly [10]. Medical records
were sought for reports coded as serious, reports suggestive of
adverse events of special interest (AESIs) [11], and reports
involving pregnancy-specific adverse events.
We searched the passive surveillance database for reports
received from November 1, 2009 through August 31, 2010 on
pregnant women vaccinated with the 2009 H1N1 vaccines. Each
report was investigated by a standard protocol at time of report
received. The protocol requested blood and tissue specimens,
which were subject for further relevant diagnostic tests, placental
or umbilical cord pathology, or fetal autopsy (Table S1). A TCDC
physician (WTH) prospectively reviewed all reports, medical
records, and results on the laboratory or pathologic investigations.
Adverse events were classified by the timing of exposure to 2009
H1N1 vaccines during the first (0–13 weeks), second (14–27 weeks)
and third ($28 weeks) trimester of pregnancy, and by the
outcomes including pregnancy-specific and nonpregnancy-specific
adverse events. We defined spontaneous abortion as natural loss of
conceptuses at ,20
th week of pregnancy and stillbirth as nonviable
conceptuses at $20
th week of gestation.
Data collection was conducted as part of a public health response
to the 2009 H1N1 pandemic and therefore did not require approval
by an institutional review board or informed consent.
Data matching and capture-recapture analysis
In addition to the passive surveillance, TCDC developed a
nationwide large-linked database (LLDB) of computerized vacci-
nations and medical records for 2009 H1N1 vaccine safety
hypothesis testing [9]. The International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) diagnoses of spontaneous
abortion (codes 631, 632, 634*, 637*, 761.8) were prospectively
collected from the daily updated National Health Insurance (NHI)
database. This LLDB had recorded 62% of the 5.6 million doses
of 2009 H1N1 vaccines administered to the Taiwan population
from November 1, 2009 through August 31, 2010 (TCDC,
unpublished data).
Because the proportion of the vaccinated population that
experiences an AEFI cannot be directly estimated with the passive
surveillance data [12], we used the capture-recapture methodology
to assess the true numbers of spontaneous abortion after 2009
H1N1 vaccination for the unadjuvanted and MF59H-adjuvanted
vaccines [13]. We matched all reports of spontaneous abortion
from the passive AEFI surveillance to cases after 2009 H1N1
vaccination that occurred between November 1, 2009 and August
31, 2010 from the LLDB on a unique identifier assigned to each
resident, date of vaccination, and date of diagnosis. The reported
dates of vaccination and diagnosis in the two data sources were
allowed to differ by up to 7 days to account for recall bias in the
passive surveillance reports. We calculated Chapman estimators of
the true number of spontaneous abortion after 2009 H1N1
vaccination as N=[(b+1)(c+1)/(a+1)]21, in which a is the number
of cases captured in both sources, b is the number of cases
captured in the passive surveillance database, and c is the number
of cases captured in the LLDB [14]. Variances for Chapman
estimators were calculated using the formula derived by Serber as
Var(N)=[(b+1)(c+1)(b2a)(c2a)]/[(a+1)
2(a+2)] [15]. A log-trans-
formation was used to obtain the 95% variance-based confidence
intervals (CIs) of N so that the lower limit was always greater than
the observed number of cases.
Risk estimation
Black et al. estimated the background rate of spontaneous
abortion to be 3.5 to 22.4 per 100 pregnancies, varying by age and
country [16]. For the general pregnant population in Taiwan,
background rates were 12.8 (95% CI, 12.8–12.9) spontaneous
abortions per 100 pregnancies according to the published
literature [17]. We calculated the capture-recapture estimated
risks of spontaneous abortion in pregnant women who received the
2009 H1N1 vaccines. The denominator data on 2009 H1N1
vaccine doses administered to pregnant women between Novem-
ber 1, 2009 and August 31, 2010 were obtained from the National
Influenza Vaccine Information System. The Influenza Vaccine
Information System monitors 2009 H1N1 vaccine utilizations in
real-time; the data distinguished doses administered by vaccine
type (the unadjuvanted or MF59H-adjuvanted vaccine), but not by
the timing of vaccination in relation to stage of pregnancy [9].
Results
From November 1, 2009 through August 31, 2010, 14,474
pregnant women received the 2009 H1N1 vaccines. Of the
14,474, 13,199 (91%) received the unadjuvanted and 1,275 (9%)
received the MF59H-adjuvanted vaccine. The enhanced passive
surveillance received 35 AEFI reports after 2009 H1N1 vaccina-
tion in pregnant women (Table 1). We verified 37 outcomes (one
woman was pregnant with triplets), including 31 pregnancy-
specific adverse events (16 spontaneous abortions, 11 stillbirths, 4
neonatal deaths), 4 nonpregnancy-specific adverse events, and 2
inadvertent immunizations in vaccine recipients who were
unaware of pregnancy at time of vaccination (Table 2). In 8 of
the 35 reports, placental/cord pathology or fetal/infant autopsy
was performed. The findings included chorioamnionitis (n=2),
trisomy 21 (n=1), cerebral hemangioblastoma (n=1), meconium
aspiration syndrome (n=1), stenosis of villi vessels (n=1), cord
stricture (n=1), and placenta accreta (n=1).
Reports after the unadjuvanted vaccine
Among 13,199 pregnant women who received the unadjuvanted
2009 H1N1 vaccine, 15 spontaneous abortions, 9 stillbirths, 3
neonatal deaths, and 3 nonpregnancy-specific adverse events were
reported (Table 2). The median days from 2009 H1N1 vaccination
to the occurrence of spontaneous abortion was 17 days (range, 0–45
days). In 7 of the 15 spontaneous abortion reports, advanced
maternal age ($35 years) were identified. One spontaneous
abortion occurred in a woman who was 36 years of age and
received the vaccine at 10
th week of pregnancy; cytogenetic analysis
identified trisomy 21. The median days from 2009 H1N1
vaccination to the occurrence of stillbirth was 18 days (range, 1–
70 days). All of the 9 stillbirths reported more than one risk
conditions associated with stillbirth [18], including maternal age
$35 years (n=3), chorioamnionitis (n=2), preterm premature
rupture of membranes (n=2), gestational diabetes mellitus (n=1),
hyperthyroidism (n=1), preeclampsia (n=1), multiple gestation
(n=1), small for gestational age fetus (n=1), fetal hydrocephalus
due to intraventricular hemorrhage (n=1), placental insufficiency
(n=1), and oligohydramnios (n=1). Cause of death for the three
neonates varied (Table 2). No major birth defect was observed for
stillbornfetuses or live-born infants who died inthe neonatal period.
The three reports involving nonpregnancy-specific adverse
events included allergic vasculitis (n=1), numbness of fingers
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vasculitis patient received the unadjuvanted 2009 H1N1 vaccine at
10
th week of pregnancy and reported onset of adverse events 10
days after vaccination. She was treated with systemic corticoste-
roids, which led to an elective termination of pregnancy due to
perceived risk of corticosteroids on fetal development.
Reports after the MF59H-adjuvanted vaccine
Reports involving the 1,275 pregnant women who received the
MF59H-adjuvanted 2009 H1N1 vaccine included one spontaneous
abortion, two stillbirths, one neonatal death, one nonpregnancy-
specific adverse event, and two inadvertent immunizations
(Table 2). Chorioamnionitis was reported in the spontaneous
abortion that occurred at 15
th week of pregnancy, 46 days after
2009 H1N1 vaccination. Onset days from 2009 H1N1 vaccination
to the occurrence of stillbirth was 7 and 32 days, respectively.
Maternal age was $35 years in one stillbirth; for the other, no
relevant risk condition associated with stillbirth could be identified.
For the infant who died within one month of birth, cause of death
was cerebral hemangioblastoma with intracranial hemorrhage.
The nonpregnancy-specific adverse event was generalized skin
rash in a woman 28 years of age, 30 days after receipt of the
Table 1. Characteristics of reports following 2009 H1N1 vaccines among pregnant women, November 1, 2009–August 31, 2010,
by vaccine type.
Characteristic Vaccine type
Unadjuvanted vaccine MF59H-adjuvanted vaccine
(n=28) (n=7)
Serious reports
a, n (%) 14 (50) 3 (43)
Maternal deaths, n (%) 0 (0) 0 (0)
Median maternal age (range), y 34 (18–42) 31 (21–36)
Median onset interval (range), d 19.5 (0–70) 32 (7–46)
Median gestational age at time of onset (range), w 16.5 (6–40) 20 (15–37)
Gestational age
b at time of vaccination, n (%)
First trimester 10 (36) 4 (57)
Second trimester 13 (46) 1 (14)
Third trimester 5 (18) 2 (29)
aReports were categorized as serious if they resulted in death, life-threatening illness, hospitalization, prolongation of an existing hospitalization, permanent disability,
or congenital anomaly.
bFirst trimester, 0–13 weeks; second trimester, 14–27 weeks; third trimester, $28 weeks of pregnancy.
doi:10.1371/journal.pone.0023049.t001
Table 2. Adverse events following 2009 H1N1 vaccines among pregnant women, November 1, 2009–August 31, 2010, by vaccine
type and timing of vaccination.
Adverse event Timing of vaccination
a
First trimester Second trimester Third trimester
Unadjuvanted
vaccine
MF59H-
adjuvanted
vaccine
Unadjuvanted
vaccine
MF59H-
adjuvanted
vaccine
Unadjuvanted
vaccine
MF59H-
adjuvanted
vaccine
(n=10) (n=4) (n=15) (n=1) (n=5) (n=2)
Pregnancy-specific
Spontaneous abortion 9 1 6 0 0 0
Stillbirth 0 0 7 1 2 1
Neonatal death 0 0 2
b 01
c 1
d
Nonpregnancy-specific 1
e 1
f 00 2
f 0
Inadvertent immunization 0 2
g 00 00
aFirst trimester, 0–13 weeks; second trimester, 14–27 weeks; third trimester, $28 weeks of pregnancy.
bThe causes of death were fetal anemia and hydrops fetalis (n=1) and preterm delivery at 21
st week of gestation (n=1).
cThe cause of death was hydrops fetalis caused by a-thalassemia.
dThe cause of death was cerebral hemangioblastoma with intracranial hemorrhage.
eThe patient received the 2009 H1N1 vaccine at 10
th week of pregnancy and developed allergic vasculitis 10 days after vaccination. She was treated with systemic
corticosteroids, which led to an elective termination of pregnancy due to perceived risk of corticosteroid on fetal development.
fThe reported adverse events were generalized rash for the MF59H-adjuvanted vaccine; and numbness of fingers (n=1) and dizziness, tremor, and rhinorrhea (n=1) for
the unadjuvanted vaccine.
gOne of the pregnant women delivered a healthy male infant at 39
th week of gestation. The outcome for the other pregnant woman was not specified in the report.
doi:10.1371/journal.pone.0023049.t002
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th week of
pregnancy.
Capture-recapture estimators and risk assessment
Sixteen cases of spontaneous abortion after 2009 H1N1
vaccination were identified in the passive surveillance database
and 135 cases were identified in the LLDB; 6 matches occurred
between the two sources. We estimated that the true number of
spontaneous abortion in pregnant women who received the 2009
H1N1 vaccines to be 329 (95% CI, 196–553) and reporting
completeness of the passive surveillance to be 5% (95% CI, 3%–
8%). The estimated risk of spontaneous abortion for the 14,474
pregnant women who received 2009 H1N1 vaccines was 2.3 (95%
CI, 1.4–3.8) per 100 pregnancies, compared with a local
background rate of 12.8 (95% CI, 12.8–12.9) per 100 pregnancies.
Table 3 showed the number of spontaneous abortion ascer-
tained from the combinations of capturing data sources for
different types of 2009 H1N1 vaccines. We estimated that risk of
spontaneous abortion was 2.2 (95% CI, 1.3–4.0) and 2.0 (95% CI,
2.0–2.0) per 100 pregnancies associated with the unadjuvanted
and MF59H-adjuvanted vaccine, respectively.
Discussion
We summarized the adverse event profile of 14,474 pregnant
women who received the 2009 H1N1 vaccines in Taiwan. Most
adverse events reported were consistent with those described
following administration of inactivated seasonal influenza vaccine
to pregnant women [19]. Review of reports did not find any
concerning pattern of adverse pregnant or fetal outcomes.
The inactivated seasonal influenza vaccine without adjuvant has
been considered safe when administered during pregnancy [4–
6,20], and the few postlicensure studies that have been published
also supported the safety of unadjuvanted 2009 H1N1 vaccine in
pregnant women [21,22]. Compared with the unadjuvanted
product, fewer data have been available on exposure to MF59H-
adjuvanted influenza vaccine in pregnancy. A review of the
Novartis pregnancy database for 43 reported exposures to MF59H-
adjuvanted influenza vaccines found that the distribution of
pregnant outcomes was similar in subjects exposed to MF59H-
adjuvanted and unadjuvanted products at any time of pregnancy
[8]. However, the inclusion of only 43 pregnancies limited the
ability to conclude on risks associated with exposure to MF59H-
adjuvanted influenza vaccines [23]. Our study provided one of the
few assessments on the safety of 2009 H1N1 vaccine adjuvanted
with MF59H based on postlicensure data involving 1,275 pregnant
recipients. Data are reassuring regarding the safety of MF59H-
adjuvanted 2009 H1N1 vaccine in pregnancy.
AEFI reporting rates in our study needed cautious interpreta-
tion because data collected through the passive surveillance was
underreported [12]. Reporting completeness of passive AEFI
surveillance can vary but is not routinely available [13,24,25].
Information on the magnitude of underreporting would be
essential to evaluate an association between 2009 H1N1 vaccine
and a reported adverse event. In Taiwan, reporting completeness
of the passive surveillance for spontaneous abortion after 2009
H1N1 vaccination was estimated to be 5%, but accuracy of this
estimate was limited by the equal likelihood of capture assumption
of the capture-recapture method [26]. Spontaneous abortion with
increasing onset interval from vaccination was less likely to be
captured by the passive surveillance system [13,24]. In addition,
the type of facility where a person received the 2009 H1N1
vaccine could also affect case ascertainment by the LLDB. At
provider offices, vaccination details were electronically transmitted
to the LLDB through NHI computerized database; however,
immunization records at schools, workplaces, or mass vaccination
stations were maintained in paper forms and would have to be
manually computerized [9]. Pregnant women who received the
2009 H1N1 vaccine at provider offices were more likely than
others vaccinated elsewhere to be captured by the LLDB.
The estimated risks of spontaneous abortion in pregnant women
receiving the unadjuvanted or MF59H-adjuvanted product were
lower than background rates for the general pregnant population
[16,17]. The comparisons to background rates, however, have
some limitations. Most spontaneous abortions occur within the
first trimester of pregnancy and the rate declines throughout
pregnancy [27]. Our study did not allow risk calculations for each
trimester because the denominator data was based on number of
2009 H1N1 vaccine doses administered to women at all stages of
pregnancy; therefore, we may have underestimated the risk of
spontaneous abortion after 2009 H1N1 vaccination. Receipt of
2009 H1N1 vaccine is voluntary and thus may be preferentially
sought by motivated and healthier individuals. In practice,
clinicians may not have vaccinated patients perceived to be at
risk for adverse pregnant outcomes. These would result in a
preferential receipt of 2009 H1N1 vaccines by a relatively healthy
pregnant population (‘‘healthy vaccinee phenomenon’’) [28].
Spontaneous abortions have been reported among pregnant
women with 2009 H1N1 infections [3]. There also have been
reports of higher miscarriage rates during previous influenza
Table 3. Distribution of cases of spontaneous abortion following 2009 H1N1 vaccines from the passive surveillance and large-
linked databases, November 1, 2009–August 31, 2010, by vaccine type.
Vaccine type Capturing source
Number of cases
ascertained
Capture-recapture estimator
of total cases (95% CI
a)
Passive surveillance
database Large-linked database
Unadjuvanted vaccine Yes Yes 5 295 (167–522)
Yes No 10
No Yes 105
MF59H-adjuvanted vaccine Yes Yes 1 25 (25–25)
Yes No 0
No Yes 24
aCI, confidence interval.
doi:10.1371/journal.pone.0023049.t003
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H1N1 vaccine might have been protected from influenza infection
and therefore, were less likely to develop spontaneous abortions
than the unvaccinated group.
This study shared other inherent limitations of all passive
surveillance systems [12]. Although clinical reviews of medical
records for reports involving pregnancy-specific adverse events
could improve data quality and completeness, limitations such as
reporting biases and lack of a controlled unvaccinated remained.
Therefore, these data cannot be used to determine whether a
vaccine causes an adverse event. Our study collected only
information about adverse events that occurred after the
administration of 2009 H1N1 vaccine and did not have all the
information essential for epidemiologic assessments of causality. It
is not known if the women who received the 2009 H1N1 vaccine
were different in baseline characteristics or at higher risk for
adverse pregnant or fetal outcomes compared with the general
pregnant population.
Nevertheless, the passive AEFI surveillance provided rapid
initial assessment of adverse pregnant and fetal outcomes, but it is
only part of the 2009 H1N1 vaccine safety monitoring activities in
Taiwan [9]. Taiwan has developed an infrastructure to actively
follow up with women who received the 2009 H1N1 vaccines at
different stages of pregnancy, as well as to follow their fetal and
newborn outcomes, using comparison groups [9]. Data from these
ongoing studies can provide further information on the safety of
2009 H1N1 vaccines in pregnant women.
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